A study by Permody-Pachuta et al. presented intriguing data suggesting that adiponectin may be a promising biomarker for assessing the efficacy of treatment in therapy-resistant depression (TRD) [91]. The gene discussed is ADIPOQ; the disease is depressive symptom measurement.